

**RECEIVED
CENTRAL FAX CENTER****APR 10 2008**

Application No. 10/758,237

AMENDMENTS TO THE CLAIMS

A detailed listing of all claims that are, or were, in the present application, irrespective of whether the claim(s) remains under examination in the application are presented below. The claims are presented in ascending order and each includes one status identifier.

1. (Previously Presented) A transposon comprising
a transcriptional unit flanked by at least one CTCF-binding domain on each side of the transcriptional unit, wherein the transcriptional unit comprises an exogenous nucleic acid for introduction into a cell, wherein the transposon comprises at least two inverted repeat sequences that specifically bind to a Sleeping Beauty transposase.
- 2-4. (Cancelled)
5. (Withdrawn) The transposon of claim 1, wherein the insulator element comprises a 16-base sequence that has at least 80% identity with SEQ ID NO:16.
6. (Withdrawn) The transposon of claim 1, wherein the insulator element comprises a 16-base sequence that has at least 80% identity with SEQ ID NO:17.
7. (Withdrawn) The transposon of claim 1, wherein the insulator element comprises a 16-base sequence that has at least 80% identity with SEQ ID NO:18.

Application No. 10/758,237

8. (Withdrawn) The transposon of claim 1, wherein the insulator element comprises at least one of SEQ ID NO: 16, SEQ ID NO:17, OR SEQ ID NO:18.

9-18 (Cancelled)

19. (Previously Presented) The transposon of claim 1, wherein the CTCF-binding domains on each side of the transcriptional unit are disposed between inverted repeats of a transposon.

20. (Original) The transposon of claim 1, wherein the transcriptional unit further comprises at least one member of the group consisting of promoters and enhancers.

21. (Original) The transposon of claim 1 wherein the exogenous nucleic acid encodes a marker molecule.

22. (Original) The transposon of claim 1 wherein the exogenous nucleic acid is a member of the group consisting of DNA encoding an antisense RNA or siRNA.

23. (Currently Amended) The transposon of claim 1 wherein the exogenous nucleic acid ~~is a member of the group consisting of DNA~~ encodes an mRNA.

24. (Cancelled)

Application No. 10/758,237

25. (Original) The transposon of claim 1 further comprising a suicide sequence nucleic acid.
26. (Currently Amended) The transposon of claim 25 further comprising a promoter for the suicide sequence nucleic acid that is independent with respect to [[a]] promoters of the exogenous nucleic acid.
27. (Previously Presented) An isolated cell, the isolated cell comprising the transposon of claim 1.
28. (Previously Presented) The isolated cell of claim 27, wherein the cell is in vitro.
- 29-30 (Cancelled).
31. (Original) The cell of claim 27, wherein the cell is transfected with the transposon.
32. (Original) The cell of claim 27, wherein the cell is electroporated with the transposon.
33. (Original) The cell of claim 27, wherein the cell is microinjected with the transposon.
34. (Original) The cell of claim 27, wherein the cell is electroporated or microinjected with the transposon, and the cell produces a protein that is encoded by the exogenous nucleic acid.

Application No. 10/758,237

35. (Original) The cell of claim 27, wherein the cell is transfected with the exogenous nucleic acid and produces a protein that is encoded by the exogenous nucleic acid.
36. (Withdrawn) The cell of claim 27, wherein the cell is a member of the group consisting of lymphocytes, pancreatic cells, neural cells, muscle cells, and blood cells.
37. (Original) The cell of claim 27, wherein the cell is a member of the group consisting of hepatocytes, hepatoma cells, primary hepatocytes and liver cells.
38. (Withdrawn) The cell of claim 27 wherein the cell wherein the cell is a stem cell.
39. (Withdrawn) The cell of claim 27, wherein the cell wherein the cell is a member of the group consisting of primary pancreatic cells and pancreatic stem cells.
40. (Withdrawn) The cell of claim 27, wherein the cell wherein the cell is a member of the group consisting of primary hematopoietic cells and hematopoietic stem cells.
41. (Previously Presented) The cell of claim 35, wherein the protein is a marker.
42. (Previously Presented) The cell of claim 35, wherein the protein is a therapeutic protein.

Application No. 10/758,237

43. (Previously Presented) The cell of claim 42, wherein the therapeutic protein ameliorates a medical condition.

44 -84 (Cancelled)

85. (Previously Presented) A transposon comprising a transcriptional unit and a CTCF-binding domain for preventing regulation of transcription of host nucleic acid by the transcriptional unit following insertion into a host mammalian cell, wherein the transposon comprises at least two inverted repeat sequences that specifically bind to a Sleeping Beauty transposase.

86. (Original) The transposon of claim 85 wherein the host nucleic acid is a gene.

87. (Original) The transposon of claim 85 wherein the transcriptional unit comprises an exogenous nucleic acid.

88- 89 (Cancelled).

90. (Original) The transposon of claim 85, wherein the transcriptional unit is disposed between a first insulator element and a second insulator element, and the first insulator element and the second insulator element are disposed between the at least two inverted repeats.

Application No. 10/758,237

91. (Original) The transposon of claim 85, wherein the transcriptional unit further comprises at least one member of the group consisting of promoters and enhancers.

92. (Original) The transposon of claim 85 wherein the transcriptional unit encodes a marker molecule.

93. (Previously Presented) An isolated cell, the isolated cell comprising the transposon of claim 85.

94. (Original) The cell of claim 93, wherein the cell is in vitro.

95-97. (Cancelled)

98. (Withdrawn) The transposon of claim 85, wherein the means for preventing regulation of transcription of host nucleic acid comprises a 16-base sequence that has at least 80% identity with SEQ ID NO:16

99. (Withdrawn) The transposon of claim 85, wherein the means for preventing regulation of transcription of host nucleic acid comprises a 16-base sequence that has at least 80% identity with SEQ.ID NO:17

Application No. 10/758,237

100. (Withdrawn) The transposon of claim 85, wherein the means for preventing regulation of transcription of host nucleic acid comprises a 16-base sequence that has at least 80% identity with SEQ ID NO:18.

101. (Withdrawn) The transposon of claim 85, wherein the means for preventing regulation of transcription of host nucleic acid comprises at least one member of the group consisting of SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18.

102. (Original) The transposon of claim 85 wherein the transcriptional unit is a member of the group consisting of antisense DNA, DNA, and cDNA.